Autolus Therapeutics (NASDAQ:AUTL) Trading 4.9% Higher

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price traded up 4.9% during mid-day trading on Thursday . The stock traded as high as $5.84 and last traded at $5.76. 96,602 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 1,590,178 shares. The stock had previously closed at $5.49.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Truist Financial increased their target price on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Monday, March 18th. Needham & Company LLC reissued a "buy" rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Thursday, March 14th. Finally, The Goldman Sachs Group increased their target price on shares of Autolus Therapeutics from $3.20 to $4.80 and gave the stock a "neutral" rating in a report on Wednesday, December 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $7.96.

Autolus Therapeutics Trading Up 0.4 %

The stock has a market capitalization of $1.47 billion, a P/E ratio of -4.61 and a beta of 1.90. The business has a 50-day moving average price of $6.13 and a 200 day moving average price of $4.89.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. UBS Group AG boosted its position in shares of Autolus Therapeutics by 2.8% during the 4th quarter. UBS Group AG now owns 84,655 shares of the company's stock valued at $545,000 after acquiring an additional 2,345 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Autolus Therapeutics by 337.3% in the fourth quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company's stock worth $27,000 after buying an additional 3,292 shares during the last quarter. Cetera Investment Advisers lifted its position in Autolus Therapeutics by 2.9% in the first quarter. Cetera Investment Advisers now owns 141,600 shares of the company's stock worth $261,000 after buying an additional 4,000 shares during the last quarter. EWA LLC lifted its position in Autolus Therapeutics by 40.2% in the fourth quarter. EWA LLC now owns 25,678 shares of the company's stock worth $155,000 after buying an additional 7,361 shares during the last quarter. Finally, LPL Financial LLC lifted its position in Autolus Therapeutics by 39.2% in the fourth quarter. LPL Financial LLC now owns 32,300 shares of the company's stock worth $61,000 after buying an additional 9,100 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.